Group Health Cooperative of Puget Sound Oncology Consortium

Seattle, Washington 98112

0 studies enrolling now · 6 studies all time

What they study most

Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Estrogen Receptor Positive Breast Cancer, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Gastrointestinal Stromal Tumor, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Progesterone Receptor Positive Tumor, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma

Studies at this site

• Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer — Completed
• S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer — Stopped early
• Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer — Completed
• Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor — Stopped early
• Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy — Completed
• Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer — Completed